Retrospective analysis of hospitalization rates in patients with schizophrenia 12 months before and 12 months after the switch to once-monthly long-acting injectable paliperidone palmitate

Sanja Totić Poznanović; Miloš Marković

doi:10.2298/VSP221114007T

Sanja Totić Poznanović University Clinical Center of Serbia, Clinic for Psychiatry, Belgrade, Serbia
Miloš Marković Clinic for Mental Disorders “Dr. Laza Lazarević”, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP221114007T

Keywords: antipsychotic agents, delayed-action preparations, drug-related adverse effect and adverse reactions, hospitalization, paliperidone palmitate, patient compliance, schizofrenia, serbia

Abstract

Background/Aim. There is no available published data about the use of long-acting injectable paliperidone palmitate (PP) in schizophrenia patients in the Republic of Serbia. The aim of this study was to assess hospitalization rates before and after the switch to once-monthly long-acting injectable PP in schizophrenia patients, as well as their compliance with this drug. Methods. We conducted a retrospective cross-sectional study in which hospitalization rates were evaluated 12 months before and 12 months after the switch to once-monthly long-acting injectable PP in 113 schizophrenia patients. The age of the enrolled patients was between 18 and 66 years. Results. The average age of the enrolled patients was 38.36 ± 11.62 years. Among them, 77 (68.1%) were male, and 36 (31.9%) were female. Out of the total number of 113 patients treated with once-monthly injectable PP, 78 (69.03%) were on monotherapy, while 35 (30.97%) had one additional oral antipsychotic (risperidone, olanzapine, aripiprazole, or clozapine). Out of the total number of 113 patients, 68 (60.18%) were not hospitalized in the 12-month period before the switch to once-monthly long-acting injectable PP, while 45 (39.82%) were hospitalized in the same period. Given that 8 patients out of the total number of 113 were excluded from therapy due to an adverse event or their own decision in the period after the switch to PP, the analysis of the hospitalization rate after the switch to PP was performed for the remaining 105 patients, of which 9 (8.57%) were hospitalized in the period after the switch to PP, and 96 (91.43%) were not. Conclusion. Our results show high compliance in the treatment with once-monthly injectable PP and a positive impact of treatment with this drug on low hospitalization rate in a 12-month period in patients with schizophrenia. Considering the availability of this drug in the Republic of Serbia, these results encourage the use of once-monthly injectable PP as an important therapeutic option in schizophrenia patients.

References

1. Brohan E, Elgie R, Sartorius N, Thornicroft G; GAMIAN-Europe Study Group. Self-stigma, empowerment and perceived discrimination among people with schizophrenia in 14 European countries: the GAMIAN-Europe study. Schizophr Res 2010; 122(1–3): 232–8.

2. Republic expert committee for the development and implementation of good clinical practice guidelines. National Guide to Good Clinical Practice for diagnosing and treating schizophrenia. Belgrade: Ministry of Health of the Republic of Serbia; 2013. (Serbian)

3. Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 2020; 177(9): 868–72.

4. Ostuzzi G, Bertolini F, Tedeschi F, Vita G, Brambilla P, Del Fabro L, et al. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants. World Psychiatry 2022; 21(2): 295–307.

5. Lin D, Joshi K, Keenan A, Shepherd J, Bailey H, Berry M, et al. Associations Between Relapses and Psychosocial Outcomes in Patients With Schizophrenia in Real-World Settings in the United States. Front Psychiatry 2021; 12: 695672.

6. Pennington M, McCrone P. The Cost of Relapse in Schizophrenia. Pharmacoeconomics 2017; 35(9): 921–36.

7. Lysaker PH, Pattison ML, Leonhardt BL, Phelps S, Vohs JL. Insight in schizophrenia spectrum disorders: relationship with behavior, mood and perceived quality of life, underlying causes and emerging treatments. World Psychiatry 2018; 17(1): 12–23.

8. Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol 2014; 4(5): 198–219.

9. Medicines and Medical Devices Agency of Serbia. Search of medicines and medical devices [Internet]. Republic of Serbia: Medicines and Medical Devices Agency of Serbia; [cited 2022 Dec 11]. Available from: https://www.alims.gov.rs/humani-lekovi/pretrazivanje-humanih-lekova/

10. U.S. Food and Drug Administration. Drug Approvals and Databases [Internet]. USA: Food and Drug Administration; [cited 2022 Dec 11]. Available from: https://www.fda.gov/drugs/
/>development-approval-process-drugs/drug-approvals-and-data
bases

11. European Medicines Agency. Medicines [Internet]. European Union: The European Medicines Agency; [cited 2022 Dec 11]. Available from: https://www.ema.europa.eu/en
/medicines

12. Kane JM, McEvoy JP, Correll CU, Llorca PM. Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia. CNS Drugs 2021; 35(11): 1189–205.

13. Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. J Clin Psychiatry 2016; 77(Suppl 3): 1–24.

14. Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry 2021; 8(5): 387–404.

15. Leucht S, Samara M, Heres S, Davis JM. Dose Equivalents for Antipsychotic Drugs: The DDD Method. Schizophr Bull 2016; 42(Suppl 1): S90–4.

16. Gutiérrez-Rojas L, Sánchez-Alonso S, García Dorado M, López Rengel PM. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain. CNS Drugs 2022; 36(5): 517–27.

17. Marques-Teixeira J, Amorim G, Pires AC. Results from PSIPROSPER: A multicenter retrospective study to analyze the impact of treatment with paliperidone palmitate 1-month on clinical outcomes and hospital resource utilization in adult patients with schizophrenia in Portugal. Front Psychiatry 2022; 13: 992256.

18. Devrimci-Ozguven H, Atmaca M, Baran Z, Cengisiz C, Çinar C, Erol A, et al. Efficacy and Safety of Paliperidone Palmitate Treatment in Patients With Schizophrenia: A Real-World Multicenter, Retrospective, Mirror-Image Study. J Clin Psychopharmacol 2019; 39(6): 604–10.

19. Fernández-Miranda JJ, Díaz-Fernández S. Tolerability of effective high doses of paliperidone palmitate in patients with severe resistant schizophrenia. Int Clin Psychopharmacol 2017; 32(1): 6–12.